Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Apr;65(4):798–803. doi: 10.1172/JCI109730

Adverse Effects of Cytomegalovirus Vaccination in Mice

M Colin Jordan 1
PMCID: PMC434465  PMID: 6244333

Abstract

Studies of live attenuated cytomegalovirus (CMV) vaccine have recently been initiated in man. The possibilities of latent infection and disease resulting from reactivation of vaccine virus are major concerns. Because markers for attenuation of tissue culture-passaged mouse CMV (MCMV) exist, studies of potential adverse effects of vaccination were initiated in mice. Plaque-purified MCMV was passed 12 times in cell culture (“vaccine virus”) and shown to be attenuated by virtue of loss of lethality and diminished replication in reticuloendothelial organs of normal mice. Although subcutaneous inoculation of 105 plaque-forming units of wild virus was lethal for mice immunosuppressed with antilymphocyte serum (18/18 died), “vaccine MCMV” killed only 3/18 (P < 0.05) and was thus shown to be highly attenuated even in immunosuppressed animals. 4 mo after subcutaneous inoculation of vaccine MCMV, no infectious virus was detectable in the tissues of normal C3H mice. However, immunosuppression with anti-lymphocyte serum and cortisone caused MCMV reactivation, dissemination, and wide-spread cytomegalic inclusion disease in 19 of 20 animals. Characterization of the reactivating virus recovered from salivary glands indicated that reversion to virulence had occurred. Thus, vaccine MCMV, although markedly attenuated initially, established latent infection, reactivated after immunosuppression, and reverted to virulence, at least in salivary gland tissue. These data from the murine model substantiate the need for careful surveillance and virologic study of patients given experimental CMV vaccine.

Full text

PDF
798

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdallah P. S., Mark J. B., Merigan T. C. Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med. 1976 Sep;61(3):326–332. doi: 10.1016/0002-9343(76)90368-5. [DOI] [PubMed] [Google Scholar]
  2. Brody A. R., Craighead J. E. Pathogenesis of pulmonary cytomegalovirus infection in immunosuppressed mice. J Infect Dis. 1974 Jun;129(6):677–689. doi: 10.1093/infdis/129.6.677. [DOI] [PubMed] [Google Scholar]
  3. Elek S. D., Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. 1974 Jan 5;1(7845):1–5. doi: 10.1016/s0140-6736(74)92997-3. [DOI] [PubMed] [Google Scholar]
  4. Glazer J. P., Friedman H. M., Grossman R. A., Starr S. E., Barker C. F., Perloff L. J., Huang E. S., Plotkin S. A. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med. 1979 Nov;91(5):676–683. doi: 10.7326/0003-4819-91-5-676. [DOI] [PubMed] [Google Scholar]
  5. Hanshaw J. B. Congenital cytomegalovirus infection: a fifteen year perspective. J Infect Dis. 1971 May;123(5):555–561. doi: 10.1093/infdis/123.5.555. [DOI] [PubMed] [Google Scholar]
  6. Henson D., Neapolitan C. Pathogenesis of chronic mouse cytomegalovirus infection in submaxillary glands of C3H mice. Am J Pathol. 1970 Feb;58(2):255–267. [PMC free article] [PubMed] [Google Scholar]
  7. Howard R. J., Balfour H. H., Jr Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus. Proc Soc Exp Biol Med. 1977 Nov;156(2):365–368. doi: 10.3181/00379727-156-39937. [DOI] [PubMed] [Google Scholar]
  8. Jordan M. C. Interstitial pneumonia and subclinical infection after intranasal inoculation of murine cytomegalovirus. Infect Immun. 1978 Jul;21(1):275–280. doi: 10.1128/iai.21.1.275-280.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Just M., Buergin-Wolff A., Emoedi G., Hernandez R. Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection. 1975;3(2):111–114. doi: 10.1007/BF01641052. [DOI] [PubMed] [Google Scholar]
  10. MANNINI A., MEDEARIS D. N., Jr Mouse salivary gland virus infections. Am J Hyg. 1961 May;73:329–343. doi: 10.1093/oxfordjournals.aje.a120192. [DOI] [PubMed] [Google Scholar]
  11. Mayo D. R., Armstrong J. A., Ho M. Reactivation of murine cytomegalovirus by cyclophosphamide. Nature. 1977 Jun 23;267(5613):721–723. doi: 10.1038/267721a0. [DOI] [PubMed] [Google Scholar]
  12. Mayo D., Armstrong J. A., Ho M. Activation of latent murine cytomegalovirus infection: cocultivation, cell transfer, and the effect of immunosuppression. J Infect Dis. 1978 Dec;138(6):890–896. doi: 10.1093/infdis/138.6.890. [DOI] [PubMed] [Google Scholar]
  13. Neff B. J., Weibel R. E., Buynak E. B., McLean A. A., Hilleman M. R. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979 Jan;160(1):32–37. doi: 10.3181/00379727-160-40382. [DOI] [PubMed] [Google Scholar]
  14. Neiman P. E., Reeves W., Ray G., Flournoy N., Lerner K. G., Sale G. E., Thomas E. D. A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis. 1977 Dec;136(6):754–767. doi: 10.1093/infdis/136.6.754. [DOI] [PubMed] [Google Scholar]
  15. Olding L. B., Jensen F. C., Oldstone M. B. Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med. 1975 Mar 1;141(3):561–572. doi: 10.1084/jem.141.3.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Osborn J. E., Walker D. L. Virulence and attenuation of murine cytomegalovirus. Infect Immun. 1971 Feb;3(2):228–236. doi: 10.1128/iai.3.2.228-236.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Plotkin S. A., Farquhar J., Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis. 1976 Nov;134(5):470–475. doi: 10.1093/infdis/134.5.470. [DOI] [PubMed] [Google Scholar]
  18. Reynolds D. W., Stagno S., Stubbs K. G., Dahle A. J., Livingston M. M., Saxon S. S., Alford C. A. Inapparent congenital cytomegalovirus infection with elevated cord IgM levels. Casual relation with auditory and mental deficiency. N Engl J Med. 1974 Feb 7;290(6):291–296. doi: 10.1056/NEJM197402072900601. [DOI] [PubMed] [Google Scholar]
  19. Selgrade M. K., Osborn J. E. Role of macrophages in resistance to murine cytomegalovirus. Infect Immun. 1974 Dec;10(6):1383–1390. doi: 10.1128/iai.10.6.1383-1390.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shanley J. D., Jordan M. C., Cook M. L., Stevens J. G. Pathogenesis of reactivated latent murine cytomegalovirus infection. Am J Pathol. 1979 Apr;95(1):67–80. [PMC free article] [PubMed] [Google Scholar]
  21. Weller T. H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II. N Engl J Med. 1971 Jul 29;285(5):267–274. doi: 10.1056/NEJM197107292850507. [DOI] [PubMed] [Google Scholar]
  22. Wu B. C., Dowling J. N., Armstrong J. A., Ho M. Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science. 1975 Oct 3;190(4209):56–58. doi: 10.1126/science.170676. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES